Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 3/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508998 | 1.00 | CTSD (0.37) | CTSDBACE1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4510222 | 0.92 | CYP11B1 (0.36) | CTSDBACE1MEN1KMT2AHCRTR1 | |
| SCHEMBL27762201 | 0.90 | CTSD (0.36) | CTSDBACE1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4512205 | 0.89 | HSD11B1 (0.36) | MEN1KMT2ASMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL4491513 | 0.89 | CETP (0.41) | CETP | |
| SCHEMBL4497300 | 0.87 | CETP (0.34) | MEN1KMT2ASMN1; SMN2CETP | |
| SCHEMBL4507659 | 0.87 | CETP (0.34) | MEN1KMT2ASMN1; SMN2CETP | |
| SCHEMBL4517595 | 0.83 | CETP (0.36) | CTSDBACE1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4500622 | 0.83 | CTSD (0.37) | CTSDBACE1HCRTR1HCRTR2CETP | |
| SCHEMBL4721981 | 0.83 | CTSD (0.37) | CTSDBACE1HCRTR1HCRTR2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | CYP46A1, CBX3, CDYL | CTSD 488/4885BACE1 1941/4885MEN1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.